Epigenetic Drugs And Diagnostic Technologies Market Growth Insights | 2027 Industry Value Touches US$ 28,606.6 Million in Terms of Revenue | by CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd. etc
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Epigenetic therapy is the use of drugs or other epigenome-influencing techniques to treat medical conditions such as cancer, heart disease, diabetes, and mental illnesses. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic use.
Statistics:
The global epigenetic drugs and diagnostic technologies market is estimated to account for US$ 28,606.6 Mn in terms of 2027.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/4026
Global Epigenetic Drugs and Diagnostic Technologies Market: Drivers
Approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period. For instance, in January 2020, the U.S. Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Global Epigenetic Drugs and Diagnostic Technologies Market: Opportunities
Adoption of Artificial Intelligence (AI) for R&D in epigenetic drugs is expected to offer lucrative growth opportunities for players in the global epigenetic drugs and diagnostic technologies market. Epigenetic drug targets are particularly suited for AI studies. The use of AI in pre-clinical drug discovery offers the potential to reduce the cycle time for lead identification.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4026
Global Epigenetic Drugs and Diagnostic Technologies Market: Restraints
Unique reactions of each patient to drugs leads to various challenges for the scientists and researchers studying genomic alterations and their phenotypic expression, which is expected to hinder growth of the market.
Key Takeaways:
The global epigenetic drugs and diagnostic technologies market was valued at US$ 6,800.3 Mn in 2019 and is forecast to reach a value of US$ 28,606.6 Mn by 2027 at a CAGR of 19.7% between 2020 and 2027. Increasing approval and launch of epigenetic drugs is expected to propel growth of the global epigenetic drugs and diagnostic technologies market over the forecast period.
Epigenetic Drugs segment held dominant position in the global epigenetic drugs and diagnostic technologies market in 2019, accounting for 71.5% share in terms of value, increasing prevalence of cancer is expected to propel growth of the segment during the forecasted period.
Market Trends
Players in the market are focused on R&D of new drugs to expand their product portfolio. For instance, in July 2020, Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics for R&D of novel therapies, presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020.
Major players in the market are also focused on raising funds for R&D of new technologies. For instance, in June 2020, Base Genomics, an epigenetics company, raised US$ 11 million to progress development of its TAPS technology, a novel chemical reaction that converts methylated cytosine to thymine under mild conditions.
Global Epigenetic Drugs and Diagnostic Technologies Market: Competitive Landscape
Major players operating in the global epigenetic drugs and diagnostic technologies market include 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/epigenetics-drugs-and-diagnostic-technologies-market-3296
Global Epigenetic Drugs and Diagnostic Technologies Market: Key Developments
June 2020: Epizyme, Inc. received the U.S. Food and Drug Administration’s supplemental New Drug Application approval for TAZVERIK (tazemetostat) for the following two distinct follicular lymphoma indications.
March 2018: EpiGentek announced its technological and financial support for new skincare startup EpigenCare for development and commercialization of a personalized skincare test based on epigenetic markers.
Segmentation
Scope of the report
- Global Epigenetic Drugs and Diagnostic Technologies Market, By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- Global Epigenetic Drugs and Diagnostic Technologies Market, By Region:
- North America
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- U.S.
- Canada
- By Type:
- Latin America
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Type:
- Europe
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- By Type:
- Asia Pacific
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Type:
- Middle East
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- GCC Countries
- Israel
- Rest of Middle East
- By Type:
- Africa
- By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies
- DNA Methylation
- ChIP Technology
- Epigenetic Drugs
- By Country
- North Africa
- Central Africa
- South Africa
- By Type:
- North America
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
